Phase 4 Chronic Kidney Disease Trial, Recruiting NCT07187713 Sponsor: Ace Cells Lab Limited Condition: Chronic Kidney Disease
Back to Chronic Kidney Disease

Phase 4 Chronic Kidney Disease Trial, Recruiting

NCT07187713
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older who have kidney disease at any stage of severity, including early signs of protein in the urine, more significant protein loss, chronic kidney disease at various stages (not yet requiring dialysis), or kidney disease after a kidney transplant where protein is present in the urine
  • People who are already taking standard kidney-protective medications (such as certain blood pressure or kidney-protecting drugs) may still be eligible to participate

Who may not be able to join:

  • People who received a kidney transplant less than 12 months ago
  • People who have an active, uncontrolled infection or an unstable autoimmune condition at the time of the trial
  • People who are currently pregnant or breastfeeding
  • People who have a known allergy or sensitivity to any of the components used in the study treatment

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 14 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Prof. Dr. Mohammed Yasser Sayyed Saif, PhD, Beni Suef Univeristy

Phone: +447473922553

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Sponsor
Ace Cells Lab Limited
Registry
ClinicalTrials.gov
Start date
20 September 2025
Est. completion
31 August 2026

Where this trial is recruiting

🇪🇬 Egypt

Primary endpoints

Change in Urinary Albumin-to-Creatinine Ratio (ACR)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov